Articles Published in 2011

Quintiles sells minority interest in Invida to Menarini Group

Wednesday, November 16, 2011 09:59 AM

Quintiles has sold its minority interest in Invida, an Asia Pacific commercial solutions joint venture, to the Italy-based Menarini Group, which is acquiring Invida in its entirety. Invida was formed in 2006 by Quintiles; The Zuellig Group; and TLS Beta, an Asia investment company.

More... »

EP Clinical Trials links EudraCT and ClinicalTrials.gov

Tuesday, November 15, 2011 04:04 PM

London-based EvaluatePharma, a source for life science sector analysis, has launched its new clinical trial intelligence service, EP Clinical Trials. By linking EudraCT and ClinicalTrials.gov records, the new service delivers a unique synthesis of clinical trials information.

More... »

SVTC Technologies partners with SUSS MicroTec

Tuesday, November 15, 2011 01:18 PM

SVTC Technologies, a partner for accelerating nanotechnology development and commercialization, is partnering with SUSS MicroTec, an equipment supplier for MEMS and advanced 3D IC integration. This collaboration is targeted at supporting wafer-level processing for MEMS and 3D IC integration with focus on the newest bonding applications needed for next-generation electronics. The partnership with SUSS MicroTec continues an ongoing SVTC strategy to provide an ecosystem of partners all geared towards providing comprehensive value-added solutions to customers.

More... »

GSK launches $50 million Canada Life Sciences Innovation Fund

Tuesday, November 15, 2011 12:05 PM

GlaxoSmithKline has launched the GSK Canada Life Sciences Innovation Fund, a new national $50 million fund that will significantly advance the commercialization of scientific innovation in Canada by investing in early stage breakthrough research. The fund will identify strategic investment opportunities within Canada’s life sciences industry including academic and health institutions, translational research centres and start-up companies.

More... »

Geron focuses on cancer programs, discontinuing stem cell programs

Tuesday, November 15, 2011 11:51 AM

Geron has reported that the company will focus on its first-in-class oncology programs, effective immediately. As a consequence, the company will discontinue further development of its stem cell programs and is seeking partners for these novel assets.

More... »

CureVac, Sanofi Pasteur collaborate in $33 million research project

Tuesday, November 15, 2011 11:20 AM

CureVac has signed several agreements with Sanofi Pasteur, the vaccines division of Sanofi. Under these agreements, CureVac and Sanofi Pasteur will further develop and apply CureVac’s proprietary RNActive technology platform to the development of vaccines against several infectious diseases.

More... »

Pharmasset reports fiscal year financial results

Tuesday, November 15, 2011 10:49 AM

Princeton, N.J.-based Pharmasset, a clinical stage pharma company that discovers, develops and commercializes drugs to treat viral infections, reported a net loss of $91.2 million, or $1.25 per share, for the fiscal year ended September 30, 2011, compared to a net loss of $66.1 million, or $1.07 per share for fiscal 2010. Revenues were $0.9 million for fiscal year 2011, compared to $1.0 million for fiscal 2010. Revenues during each fiscal year primarily consist of amortization of up-front and subsequent collaborative and license payments received from Roche previously recorded as deferred revenue. 

More... »

Accelovance names chief medical officer

Monday, November 14, 2011 02:33 PM

Accelovance has named Stephan A. Bart Sr., M.D. chief medical officer. Bart will be responsible for medical affairs and site operations, focused on enhancing the level of clinical solutions Accelovance can provide to clients.

More... »

POZEN's phase I Co-Rx study shows positive results

Monday, November 14, 2011 01:32 PM

POZEN, a pharmaceutical company, has reported positive results from a phase I study comparing a dose-timing strategy of PA32540 and clopidogrel spaced 10 hours apart as compared to synchronous administration of enteric-coated (EC) omeprazole (40 mg), enteric-coated aspirin (81 mg) and clopidogrel (300 mg loading/75 mg daily).  In the Co-Rx study, PA32540, a novel combination of 325 mg of aspirin and 40 mg immediate-release (IR) omeprazole, when dosed 10 hours apart from clopidogrel, was associated with greater platelet inhibition than synchronous administration of aspirin, clopidogrel and delayed-release omeprazole (46.5% versus 39.3%, respectively, at day 7(95% CI [2.57, 11.91]). These findings are directly relevant to the treatment of patients with gastrointestinal (GI) risk who require dual antiplatelet therapy (DAPT) and gastroprotection.

More... »

Katzen Eye Group partners with RxTrials

Monday, November 14, 2011 12:06 PM

Katzen Eye Group, a private provider of eye care services in Maryland, has partnered with RxTrials, to provide clinical research study support in ophthalmology and optometry.

More... »